Acerus Reports Fourth Quarter and Full Year 2019 Financial Results

Acerus Pharmaceuticals (TSX:ASP) reported its financial results for the three and twelve-month period ended December 31, 2019.

As quoted in the press release:

2019 Highlights

• Amended and restated (“A&R”) partnership agreement with Aytu Bioscience (“Aytu”) becomes fully functional which should allow for accelerated growth of NATESTO® in the United States

• Multiple scientific publications and congress presentations highlighting the unique clinical profile of NATESTO®

• Avanafil New Drug Submission filed with Health Canada

• Multiple financing transactions in 2019 and 2020 raising over $30 million to fund future growth

Click here to read the full press release.